Sherrie L. Aspinall PharmD, MSc , Xinhua Zhao MS , Chester B. Good MD, MPH , Roslyn A. Stone PhD , Joy Boresi PharmD , Sarah Cox PharmD , Chad Bartholomew PharmD , David Jansen PharmD , Sarah Guterman PharmD , Mauricio Patino PharmD , Giselle Rivera-Miranda PharmD , Mark Burlingame PharmD , Justin Frazer PharmD , Janelle Sellers PharmD , Valerie Stanard Steele PharmD , Lauri Witt PharmD , Francesca E. Cunningham PharmD
{"title":"减少老年肾功能不全患者格列本脲使用的干预措施","authors":"Sherrie L. Aspinall PharmD, MSc , Xinhua Zhao MS , Chester B. Good MD, MPH , Roslyn A. Stone PhD , Joy Boresi PharmD , Sarah Cox PharmD , Chad Bartholomew PharmD , David Jansen PharmD , Sarah Guterman PharmD , Mauricio Patino PharmD , Giselle Rivera-Miranda PharmD , Mark Burlingame PharmD , Justin Frazer PharmD , Janelle Sellers PharmD , Valerie Stanard Steele PharmD , Lauri Witt PharmD , Francesca E. Cunningham PharmD","doi":"10.1016/j.amjopharm.2011.02.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA<sub>1c</sub>) levels and rates of serious hypoglycemia.</p></div><div><h3>Methods</h3><p>This historical cohort study included a targeted cohort of 4368 outpatient veterans aged ≥65 years with active prescriptions for glyburide between April 1, 2007 and June 30, 2007 and serum creatinine (SCr) ≥2 mg/dL and a nontargeted cohort of 1886 outpatients meeting these same criteria between July 1, 2007 and September 3, 2007. The intervention in the risk reduction project took place on September 4, 2007 and entailed giving regional pharmacy leaders information about the increased risk of hypoglycemia with glyburide and the list of targeted patients for follow up with providers. For each patient, the study period was the time between the date they first met the eligibility criteria and March 31, 2008. All data were obtained from Veterans Affairs (VA) administrative databases. The primary outcome was the discontinuation of glyburide. Secondary outcomes were the change in HbA<sub>1c</sub> after stopping glyburide and the rate of serious hypoglycemia after intervention.</p></div><div><h3>Results</h3><p>Incidence rate ratios (IRRs) for glyburide discontinuation in targeted versus nontargeted cohorts were statistically significantly elevated in September (IRR 2.1; 95% CI 1.7–2.5), October (IRR 1.3; 95% CI 1.1–1.6), and November 2007 (IRR 1.4; 95% CI 1.1–1.7). The intervention, black race, SCr, Charlson comorbidity score, new glyburide use, and VA region were independently associated with discontinuation. Among patients in the targeted cohort who discontinued glyburide, mean (SD) HbA<sub>1c</sub> at baseline and after discontinuation were 7.17% (1.35%), and 7.22% (1.34%), respectively (<em>P</em> = 0.36). The hypoglycemia rates/1000 person-days were 0.093 before the intervention and 0.070 afterwards (<em>P</em> = 0.10).</p></div><div><h3>Conclusion</h3><p>A one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with renal insufficiency without compromising glucose control.</p></div>","PeriodicalId":50811,"journal":{"name":"American Journal Geriatric Pharmacotherapy","volume":"9 1","pages":"Pages 58-68"},"PeriodicalIF":0.0000,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.02.001","citationCount":"27","resultStr":"{\"title\":\"Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency⁎\",\"authors\":\"Sherrie L. Aspinall PharmD, MSc , Xinhua Zhao MS , Chester B. Good MD, MPH , Roslyn A. Stone PhD , Joy Boresi PharmD , Sarah Cox PharmD , Chad Bartholomew PharmD , David Jansen PharmD , Sarah Guterman PharmD , Mauricio Patino PharmD , Giselle Rivera-Miranda PharmD , Mark Burlingame PharmD , Justin Frazer PharmD , Janelle Sellers PharmD , Valerie Stanard Steele PharmD , Lauri Witt PharmD , Francesca E. Cunningham PharmD\",\"doi\":\"10.1016/j.amjopharm.2011.02.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA<sub>1c</sub>) levels and rates of serious hypoglycemia.</p></div><div><h3>Methods</h3><p>This historical cohort study included a targeted cohort of 4368 outpatient veterans aged ≥65 years with active prescriptions for glyburide between April 1, 2007 and June 30, 2007 and serum creatinine (SCr) ≥2 mg/dL and a nontargeted cohort of 1886 outpatients meeting these same criteria between July 1, 2007 and September 3, 2007. The intervention in the risk reduction project took place on September 4, 2007 and entailed giving regional pharmacy leaders information about the increased risk of hypoglycemia with glyburide and the list of targeted patients for follow up with providers. For each patient, the study period was the time between the date they first met the eligibility criteria and March 31, 2008. All data were obtained from Veterans Affairs (VA) administrative databases. The primary outcome was the discontinuation of glyburide. Secondary outcomes were the change in HbA<sub>1c</sub> after stopping glyburide and the rate of serious hypoglycemia after intervention.</p></div><div><h3>Results</h3><p>Incidence rate ratios (IRRs) for glyburide discontinuation in targeted versus nontargeted cohorts were statistically significantly elevated in September (IRR 2.1; 95% CI 1.7–2.5), October (IRR 1.3; 95% CI 1.1–1.6), and November 2007 (IRR 1.4; 95% CI 1.1–1.7). The intervention, black race, SCr, Charlson comorbidity score, new glyburide use, and VA region were independently associated with discontinuation. Among patients in the targeted cohort who discontinued glyburide, mean (SD) HbA<sub>1c</sub> at baseline and after discontinuation were 7.17% (1.35%), and 7.22% (1.34%), respectively (<em>P</em> = 0.36). The hypoglycemia rates/1000 person-days were 0.093 before the intervention and 0.070 afterwards (<em>P</em> = 0.10).</p></div><div><h3>Conclusion</h3><p>A one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with renal insufficiency without compromising glucose control.</p></div>\",\"PeriodicalId\":50811,\"journal\":{\"name\":\"American Journal Geriatric Pharmacotherapy\",\"volume\":\"9 1\",\"pages\":\"Pages 58-68\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.amjopharm.2011.02.001\",\"citationCount\":\"27\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal Geriatric Pharmacotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1543594611000055\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal Geriatric Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1543594611000055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27
摘要
本研究的目的是描述格列本脲在风险降低项目和非风险降低项目目标人群中的处方变化,评估与格列本脲停药相关的因素,并评估糖化血红蛋白(即HbA1c)水平和严重低血糖发生率的变化。方法本历史队列研究纳入4368例年龄≥65岁、2007年4月1日至2007年6月30日服用格列本脲有效处方且血清肌酐(SCr)≥2 mg/dL的门诊退伍军人,以及1886例2007年7月1日至2007年9月3日符合相同标准的门诊退伍军人。降低风险项目的干预于2007年9月4日进行,包括向地区药房负责人提供格列本脲增加低血糖风险的信息,以及与供应商进行随访的目标患者名单。对于每位患者,研究期间是从他们首次符合资格标准到2008年3月31日之间的时间。所有数据均来自退伍军人事务(VA)管理数据库。主要结局是停用格列本脲。次要结局是停用格列本脲后HbA1c的变化和干预后严重低血糖的发生率。结果:9月份格列本脲停药的靶向组与非靶向组的发生率比(IRR)显著升高(IRR 2.1;95% CI 1.7-2.5), 10月(IRR 1.3;95% CI 1.1-1.6)和2007年11月(IRR 1.4;95% ci 1.1-1.7)。干预、黑人种族、SCr、Charlson合并症评分、新格列本脲的使用和VA区域与停药独立相关。在停用格列本脲的目标队列患者中,基线和停药后的平均(SD) HbA1c分别为7.17%(1.35%)和7.22% (1.34%)(P = 0.36)。干预前和干预后低血糖率分别为0.093和0.070 /1000人天(P = 0.10)。结论:降低风险项目中的一次性干预降低了老年肾功能不全门诊患者格列本脲在3个月期间的使用,且不影响血糖控制。
Intervention to Decrease Glyburide Use in Elderly Patients With Renal Insufficiency⁎
Objectives
The objectives of this study were to describe changes in glyburide prescribing in cohorts that were and were not targeted by a risk reduction project, assess factors associated with glyburide discontinuation, and evaluate changes in glycated hemoglobin (ie, HbA1c) levels and rates of serious hypoglycemia.
Methods
This historical cohort study included a targeted cohort of 4368 outpatient veterans aged ≥65 years with active prescriptions for glyburide between April 1, 2007 and June 30, 2007 and serum creatinine (SCr) ≥2 mg/dL and a nontargeted cohort of 1886 outpatients meeting these same criteria between July 1, 2007 and September 3, 2007. The intervention in the risk reduction project took place on September 4, 2007 and entailed giving regional pharmacy leaders information about the increased risk of hypoglycemia with glyburide and the list of targeted patients for follow up with providers. For each patient, the study period was the time between the date they first met the eligibility criteria and March 31, 2008. All data were obtained from Veterans Affairs (VA) administrative databases. The primary outcome was the discontinuation of glyburide. Secondary outcomes were the change in HbA1c after stopping glyburide and the rate of serious hypoglycemia after intervention.
Results
Incidence rate ratios (IRRs) for glyburide discontinuation in targeted versus nontargeted cohorts were statistically significantly elevated in September (IRR 2.1; 95% CI 1.7–2.5), October (IRR 1.3; 95% CI 1.1–1.6), and November 2007 (IRR 1.4; 95% CI 1.1–1.7). The intervention, black race, SCr, Charlson comorbidity score, new glyburide use, and VA region were independently associated with discontinuation. Among patients in the targeted cohort who discontinued glyburide, mean (SD) HbA1c at baseline and after discontinuation were 7.17% (1.35%), and 7.22% (1.34%), respectively (P = 0.36). The hypoglycemia rates/1000 person-days were 0.093 before the intervention and 0.070 afterwards (P = 0.10).
Conclusion
A one-time intervention in a risk reduction project decreased glyburide use over a 3-month period in elderly outpatients with renal insufficiency without compromising glucose control.